ReproCELL Inc.

Company Overview

Established in 2003, ReproCELL Inc. is headquartered in Yokohama, Japan. Its group companies, BioServe (U.S.), Stemgent (U.S.), Reinnervate (U.K.), and Biopta (U.K.), serve as a single-source solution for reagents, services, and training across the entire regenerative medicine workflow. The company supplies reagents to support researchers in the derivation, maintenance, and differentiation of iPS cell lines. The company is able to procure primary patient samples from both normal and a diverse array of disease backgrounds.

Stemgent’s RNA reprogramming technology allows researchers to generate clinically compliant and integration-free iPSC lines from human blood and fibroblasts in their labs or through Stemgent’s service portal. In addition to research reagents for ES/iPS culture, the company offers iPSC-derived functional cells, including human cardiomyocytes, neurons, and hepatocytes, for use in endpoint assays, as well as disease model cells generated through iPSC technologies. ReproCELL claims to be the first company to commercialize iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications.